In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis.
Aerosolized evaporative precipitation into aqueous solution and spray freezing into liquid nanostructured formulations of itraconazole as prophylaxis significantly improved survival relative to commercial itraconazole oral solution and the control in a murine model of invasive pulmonary aspergillosis. Aerosolized administration of nanostructured formulations also achieved high lung tissue concentrations while limiting systemic exposure.
Hoeben
Barbara J
BJ
University of Texas Health at Austin College of Pharmacy, TX, USA.
Burgess
David S
DS
McConville
Jason T
JT
Najvar
Laura K
LK
Talbert
Robert L
RL
Peters
Jay I
JI
Wiederhold
Nathan P
NP
Frei
Bradi L
BL
Graybill
John R
JR
Bocanegra
Rosie
R
Overhoff
Kirk A
KA
Sinswat
Prapasri
P
Johnston
Keith P
KP
Williams
Robert O
RO
D000336:Aerosols; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage*; D001228:Aspergillosis / Q000517:prevention & control*; D002626:Chemistry, Pharmaceutical; D017964:Itraconazole / Q000008:administration & dosage* / Q000097:blood; D008172:Lung Diseases, Fungal / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D049329:Nanostructures
D000336:Aerosols; D000935:Antifungal Agents; D017964:Itraconazole